The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

For the first time, there’s a date on the calendar where the legitimate version of the peptide market gets decided in public. July 23–24, 2026. Two days at the FDA’s White Oak campus in Silver Spring, where an advisory committee reviews seven peptides and recommends which ones a US pharmacy will be allowed to make you by prescription.

That’s the good news, and it’s real. The catch is in the detail: the committee is voting on specific indications, most of them nothing like what the off-label market sells these for. If you’re tracking one of these seven, the exact wording of what’s on the docket matters more than the fact that it’s on the docket at all. (What the PCAC is and what its vote does is the mechanics; this is the line-up.)

July 23 — four compounds

The docket itself comes from the April 2026 Federal Register notice 2026-07361; the FDA-reviewed indications below come off the agency’s advisory-committee calendar page for the meeting. Keep one eye on the gap between each indication and the way the compound is actually marketed.

BPC-157 — reviewed for ulcerative colitis. The peptide the injury forums built a whole stack around is on the docket for a gut condition, leaning on its mucosal-protection research. The tendon-and-joint angle every vendor sells it for isn’t what the committee is voting on.

KPV — for wound healing and inflammatory conditions. A tripeptide fragment of alpha-melanocyte-stimulating hormone. The dual indication tracks its dual mechanism: skin repair on one side, anti-inflammatory action on the other.

TB-500 — for wound healing. The thymosin-beta-4-derived peptide that anchors the other half of the injury stack. The docketed use is narrower than the marketing.

MOTs-C — for obesity and osteoporosis. This is the sharpest case of indication drift on the whole docket. MOTs-C sells across the longevity market as a mitochondrial anti-ageing peptide. The FDA is reviewing it for body composition and bone density. Different drug, on paper.

July 24 — three more

Emideltide (DSIP) — for opioid withdrawal, chronic insomnia, and narcolepsy. Emideltide is the registered name; the compound is the one most literature still calls delta sleep-inducing peptide. Three indications, all neurological.

Semax — for cerebral ischemia, migraine, and trigeminal neuralgia. A short heptapeptide developed in Russia in the 1980s for stroke recovery. Whatever the forums claim about cognitive enhancement isn’t on the ballot.

Epitalon — for insomnia. The longevity market sells this one as a telomere compound. The reviewed indication is sleep. Marketing and record, looking at different things again.

Hold onto the pattern. In every case but TB-500, the indication the committee votes on is narrower or plain different from the one the supplement market pushes. A favourable vote opens the compounding pathway for the indication on the record — and the off-label uses most buyers actually care about sit outside it.

The five queued for February 2027

The same April 2026 action scheduled a second meeting before the end of February 2027 for five more: Dihexa acetate, LL-37, GHK-Cu, PEG-MGF, and Melanotan II. The exact date isn’t published yet.

GHK-Cu is the one worth a careful line, because it shows how much the route of administration writes the story. The FDA split it in two, and the two routes moved in opposite directions. Injectable GHK-Cu — the form sold in vials off-label — came off Category 2, the do not compound list. Topical GHK-Cu was pulled off Category 1, the under evaluation list that had let compounders make it under enforcement discretion, so the cream lost a safe harbor it used to have. Both go to February; the live question is the injection. Anyone waving vaguely toward GHK-Cu and PCAC without saying which route and which direction is compressing the one detail that matters.

The peptides that already lost

Here’s the part most forum coverage gets wrong. Several compounds the market still files under PCAC peptides aren’t on the July docket, aren’t on the February docket, and aren’t awaiting review. They already had their hearing, in 2024, and the committee voted against them.

Ipamorelin went to the October 29, 2024 meeting. CJC-1295, AOD-9604, and Thymosin alpha-1 went to the December 4, 2024 meeting. All four: voted against inclusion on the 503A list. The FDA’s reasoning ran to a consistent triplet — insufficient human safety data, mechanistic concerns about unintended endocrine effects, and a lack of reproducible efficacy outside small or open-label trials. (Thymosin alpha-1 carried an extra wrinkle: it sits under biologics regulation, not the small-molecule 503A framework most peptides ride.) None of the four is getting another shot in 2026 or 2027. Not on the upcoming dockets is technically true and quietly misleading — the honest version is heard already, and lost. The fuller story of that vote is its own piece.

A separate set sits outside the PCAC question for structural reasons rather than a lost vote: sermorelin runs under an existing compounding framework after the 2009 Geref withdrawals, selank was never scheduled or voted on, tesamorelin is already an approved drug (Egrifta WR) so it can’t be on a docket for unapproved substances, and PT-141 has its own approval path as Vyleesi. Different lane, not a rejection.

What to actually watch on the day

Three things are worth reading live, if you’re following closely.

First, whether the committee’s discussion holds to the FDA-reviewed indication or drifts toward the off-label uses driving demand. Forum coverage will blur the two. The committee won’t. Whichever indication the vote attaches to is the one a future prescription has to match.

Second, the safety record FDA staff put on the table. For most of these the human evidence is thin enough to fit on one chart. How thin the staff call it matters more than the marketing volume around any single compound.

Third, the vote splits. PCAC records votes by member. A unanimous no and a narrow 8-6 yes mean very different things for the rulemaking that follows, even when the public summary flattens both into a verdict.

And then the wait. A favourable vote in July isn’t a prescription in August — the rulemaking that turns a vote into access runs months at minimum. The meeting sets direction. The rule sets the date.

Where this leaves the seven

Right now the only supply chain for all twelve peptides under review runs through research-chemical sites — vials labelled not for human consumption, no testing, no prescription, no physician. July is the first formal gate between that and a real one: a doctor’s script, a licensed pharmacy, a named indication, an assay on the batch.

Whichever peptides clear the votes on the 23rd and 24th are the ones a US pharmacy will eventually be allowed to compound. Building the operation that dispenses them the day that’s legal — supervised, licensed, tested — is the whole point of Wolverine Health. Watching the docket, not standing in front of it. Leave your email and we’ll flag the moment the regulated version of the one you’re tracking is real.